Ticker

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 46,134 shares, a decrease of 46.0% from the July 15th total of 85,412 shares. Currently, 0.0% of the company's stock are short sold. Based

Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped up prior to trading on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $14.54, but opened at $16.14. Terumo shares last traded at $16.19, with a volume of 4,271 shares trading hands. The company reported $0.30 earnings per share

Terumo (OTCMKTS:TRUMY - Get Free Report) and Lantheus (NASDAQ: LNTH - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation. Profitability This table compares Terumo and Lantheus' net margins, return

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.